Multiple myeloma is one of the most common hematologic malignancies, characterized by marked biological heterogeneity and a complex disease course. Achieving deep and durable remission at initial diagnosis is critical for improving long-term outcomes. At the recent Annual Meeting of the American Society of Hematology (ASH), Professor Du Juan’s study was selected for oral presentation, evaluating the use of dual-target BCMA/CD19 FasTCAR-T therapy as first-line treatment in patients with newly diagnosed multiple myeloma (NDMM). The encouraging results provide strong evidence supporting the earlier use of CAR-T therapy. Hematology Frontier invited Professor Du Juan for an in-depth discussion of the study and future research directions.

The 67th Annual Meeting of the American Society of Hematology (ASH) was held from December 6 to 9, 2025, in Orlando, bringing together the latest global advances in hematology research and clinical practice. At this year’s meeting, the team led by Professor Hu Kai from Beijing Gaobo Hospital presented seven studies focusing on CAR-T cell therapy across different types of relapsed/refractory lymphoma, including B-cell lymphoma, central nervous system lymphoma, T-cell lymphoma, as well as combined strategies involving CAR-T therapy and hematopoietic stem cell transplantation. These studies provide important evidence supporting the further development of individualized treatment strategies. Oncology Frontier – Hematology Frontier invited Professor Hu Kai to provide an in-depth interpretation of these key findings and their clinical significance.

The 67th Annual Meeting of the American Society of Hematology (ASH) was held grandly in Orlando from December 6 to 9, 2025, bringing together the latest research and clinical advances…